A strategist with 20 years in biotech, specializing in clinical genetics and epigenetics James in his role as the Chief Commercial Officer for EpiDisease lauches tests utilizing the genetic and epigenetic biomarkers discovered and developed by his R&D group to improve management of complex diseases. translating cutting-edge research into practical solutions that enhance patient care.
James has built and led teams globally in specialist companies such as Orphan Europe, Biogen, Biomarin and successfully launched complex biologicals treatments for cogential diseases, driving revenue growth while challenging markets to re-think patient care by connecting with key stakeholders across cultures.

James is a scientiific entrepreneur, combining his experience in the biotechnology industry with graduate and post-graduate degrees in Biochemistry and Molecular Genetics with an Executive MBA from the IE University in Madrid.